Waters Past Earnings Performance
Past criteria checks 2/6
Waters has been growing earnings at an average annual rate of 3.3%, while the Life Sciences industry saw earnings growing at 15.4% annually. Revenues have been growing at an average rate of 5.5% per year. Waters's return on equity is 38.8%, and it has net margins of 21.4%.
Key information
3.3%
Earnings growth rate
5.8%
EPS growth rate
| Life Sciences Industry Growth | 12.9% |
| Revenue growth rate | 5.5% |
| Return on equity | 38.8% |
| Net Margin | 21.4% |
| Last Earnings Update | 28 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Waters makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 28 Sep 24 | 2,905 | 623 | 690 | 180 |
| 29 Jun 24 | 2,877 | 596 | 688 | 177 |
| 30 Mar 24 | 2,909 | 604 | 690 | 177 |
| 31 Dec 23 | 2,956 | 642 | 697 | 175 |
| 30 Sep 23 | 2,995 | 653 | 690 | 179 |
| 01 Jul 23 | 2,992 | 675 | 696 | 180 |
| 01 Apr 23 | 2,966 | 689 | 682 | 178 |
| 31 Dec 22 | 2,972 | 708 | 658 | 176 |
| 01 Oct 22 | 2,950 | 697 | 658 | 171 |
| 02 Jul 22 | 2,901 | 702 | 645 | 170 |
| 02 Apr 22 | 2,868 | 705 | 641 | 171 |
| 31 Dec 21 | 2,786 | 693 | 627 | 168 |
| 02 Oct 21 | 2,736 | 695 | 606 | 165 |
| 03 Jul 21 | 2,671 | 660 | 563 | 158 |
| 03 Apr 21 | 2,509 | 616 | 541 | 144 |
| 31 Dec 20 | 2,365 | 522 | 555 | 141 |
| 26 Sep 20 | 2,295 | 504 | 507 | 138 |
| 27 Jun 20 | 2,278 | 515 | 524 | 138 |
| 28 Mar 20 | 2,358 | 537 | 522 | 143 |
| 31 Dec 19 | 2,407 | 592 | 526 | 143 |
| 28 Sep 19 | 2,405 | 577 | 582 | 144 |
| 29 Jun 19 | 2,406 | 580 | 584 | 145 |
| 30 Mar 19 | 2,403 | 591 | 589 | 144 |
| 31 Dec 18 | 2,420 | 594 | 585 | 143 |
| 29 Sep 18 | 2,392 | 55 | 543 | 140 |
| 30 Jun 18 | 2,380 | 51 | 550 | 139 |
| 31 Mar 18 | 2,342 | 27 | 540 | 136 |
| 31 Dec 17 | 2,309 | 20 | 545 | 133 |
| 30 Sep 17 | 2,251 | 548 | 512 | 130 |
| 01 Jul 17 | 2,212 | 537 | 501 | 127 |
| 01 Apr 17 | 2,190 | 533 | 502 | 127 |
| 31 Dec 16 | 2,167 | 522 | 512 | 125 |
| 01 Oct 16 | 2,125 | 498 | 508 | 121 |
| 02 Jul 16 | 2,099 | 490 | 509 | 121 |
| 02 Apr 16 | 2,057 | 467 | 502 | 119 |
| 31 Dec 15 | 2,042 | 469 | 493 | 119 |
| 03 Oct 15 | 2,040 | 469 | 498 | 119 |
| 04 Jul 15 | 2,032 | 467 | 496 | 116 |
| 04 Apr 15 | 2,019 | 457 | 501 | 112 |
| 31 Dec 14 | 1,989 | 432 | 502 | 108 |
| 27 Sep 14 | 1,971 | 422 | 501 | 106 |
| 28 Jun 14 | 1,935 | 406 | 500 | 102 |
| 29 Mar 14 | 1,904 | 399 | 495 | 100 |
| 31 Dec 13 | 1,904 | 450 | 493 | 101 |
Quality Earnings: WAT * has high quality earnings.
Growing Profit Margin: WAT *'s current net profit margins (21.4%) are lower than last year (21.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: WAT *'s earnings have grown by 3.3% per year over the past 5 years.
Accelerating Growth: WAT *'s has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: WAT * had negative earnings growth (-4.7%) over the past year, making it difficult to compare to the Life Sciences industry average (-3.9%).
Return on Equity
High ROE: Whilst WAT *'s Return on Equity (38.84%) is high, this metric is skewed due to their high level of debt.